Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION

Similar documents
Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia

Does ABCD 2 Score Below 4 Allow More Time to Evaluate Patients With a Transient Ischemic Attack?

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

Joshua A. Beckman, MD. Brigham and Women s Hospital

The TNT Trial Is It Time to Shift Our Goals in Clinical

7 th Munich Vascular Conference

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

The Impact of Smoking on Acute Ischemic Stroke

ACC NY Cardiovascular Symposium

Is Lower Better for LDL or is there a Sweet Spot

CLINICAL OUTCOME Vs SURROGATE MARKER

STATINS FOR PAD Long - term prognosis

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Is there enough evidence for DAPT after endovascular intervention for PAOD?

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects

CVD risk assessment using risk scores in primary and secondary prevention

Overlap of Diseases Underlying Ischemic Stroke The ASCOD Phenotyping

Stroke and myocardial infarction (MI) share common risk

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

PCSK9 Inhibitors and Modulators

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

La terapia antiaggregante nel paziente con stroke

How would you manage Ms. Gold

The presenter does not have any potential conflicts of interest to disclose

Permanent foramen ovale: when to close?

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

CHOLESTEROL-LOWERING THERAPHY

TIA as Acute Cerebrovascular Syndrome

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

COURAGE to Leave Diseased Arteries Alone

Prospective Natural-History Study of Coronary Atherosclerosis

The Clinical Unmet need in the patient with Diabetes and ACS

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease

HDL and Arterial Wall

Patients who experience a stroke or transient ischemic

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

Controversies in Cardiac Pharmacology

ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010

How Long Patietns Will Be on Dual Antiplatelet Therapy?

Prevalence and Determinants of Subdiaphragmatic Visceral Infarction in Patients With Fatal Stroke

44TH ANNUAL RECENT ADVANCES IN NEUROLOGY

Current and Future Imaging Trends in Risk Stratification for CAD

The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered?

Potential recommendations for CT coronary angiography in athletes

Lipids management and prevention of Stroke

Critical Review Form Therapy

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Lipid Management 2013 Statin Benefit Groups

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Rikshospitalet, University of Oslo

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

Game Strategy: High Intensity Statin in Stroke. K.M. Osei MD, MSc Cardiovascular Conference PARMC Feb 24, 2018

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES

surtout qui n est PAS à risque?

Quantifying the risk of heart disease following acute ischaemic stroke: a comprehensive meta-analysis of over 50,000 subjects For peer review only

Speakers. 2015, American Heart Association 1

Prevention of MACROvascular Complications of Diabetes

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

Which CVS risk reduction strategy fits better to carotid US findings?

Slide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure

A new era in the treatment of peripheral artery disease (PAD)?

Secondary Stroke Prevention: A Precautionary Tale

Adults With Diagnosed Diabetes

Antihypertensive Trial Design ALLHAT

JAMA. 2011;305(24): Nora A. Kalagi, MSc

The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis

Coronary Artery Disease: Revascularization (Teacher s Guide)

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?

Landmark Clinical Trials.

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

Advances in the treatment of posterior cerebral circulation symptomatic disease

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

RHU ivasc: CONSTANCES et la recherche cardiovasculaire. Ph.Gabriel STEG DHU FIRE Hôpital Bichat; AP-HP INSERM U1148 Université Paris Diderot

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Stroke Update. Lacunar 19% Thromboembolic 6% SAH 13% ICH 13% Unknown 32% Hemorrhagic 26% Ischemic 71% Other 3% Cardioembolic 14%

EVIDENCE TO DATE EVOLOCUMAB (REPATHA)

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

PAR-1 Antagonist: What Do Clinical Trials Teach Us?

Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials

In-Ho Chae. Seoul National University College of Medicine

Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014

[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]

Current Medical Therapy for

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic

TIA: Updates and Management 2008

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria

Transcription:

Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION The Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease (A.M.I.S.T.A.D.) study Pierre Amarenco, M.D., Philippa C Lavallée, M.D., Julien Labreuche, B.S., Gregory Ducrocq, M.D., Jean- Michel Juliard, Laurent Feldman, M.D., Ph.D., Lucie Cabrejo, M.D., Elena Meseguer, M.D., Céline Guidoux, M.D., Valérie Adraï, M.D., Samina Ratani, M.D., Jérôme Kusmierek, M.D., Bertrand Lapergue, M.D., Isabelle F Klein, M.D., Ph.D., Fernando Gongora-Rivera, M.D., Arturo Jaramillo, M.D., Mikael Mazighi, M.D., Ph.D., Pierre-Jean Touboul, M.D., Philippe Gabriel Steg, M.D. INSERM U-698: «Clinical Research in Atherothrombosis» and Department of Neurology and Stroke Center and of Cardiology Paris-Diderot University and Bichat University Hospital, Paris, France

DECLARATION OF CONFLICT OF INTEREST none

What is the frequency of CAD in patients with ischemic stroke? Which consequence in terms of risk of major vascular events?

Percent of patients with events Vascular Prognosis in Stroke Patients Patients with stroke had a high risk of recurrent vascular event The most frequent event after a stroke is having an another stroke 16 Stroke Myocardial Infarction 14 12 10 8 14% 10% 13% 8% 9% 6 4 2 3% 3% 2% 2% 1.9% CATS CAPRIE* ESPS 2 MATCH PRoFESS Modified from Albers, Neurology. 2000;14;54(5):1022-8. * Stroke patient subgroup only (n = 6,431)

Vascular Prognosis in Stroke Patients % The risk of Myocardial Infarction increases with time Cumulative risk of Non Fatal and Fatal Stroke and Cardiac events in the NOMAS Study Dhamoon MS, et al. Neurology. 2006;66:641-646.

Vascular Prognosis in Stroke Patients Cumulative risk of Fatal Cardiac events in the NOMAS Study Dhamoon MS, et al. Neurology. 2006;66:641-646.

Cerebrovascular Disease Patient Profile: REACH registry CVD population N=18,957 RISK FACTORS ONLY CAD N=5,704 CVD N=11,339 N=1,120 PAD N=794 Total: N=63,129 TIA: N=8,741 (48%) Stroke: N=13,650 (73%) Of the total CVD population: 40.2% have more than 1 disease location 34.3% have 2 disease locations 5.9% have 3 disease locations --> Polyvascular disease

Percent 18,957 PATIENTS WITH CerebroVascular Disease (CVD) 1-year cardiovascular event rates as function of number of symptomatic disease locations* 8 6 4 CVD Alone + CAD + PAD + CAD + PAD 3,6 3,5 3,7 4,8 4,0 4,5 6,4 7,0 7,4 2 1,4 2,0 1,8 1,6 1,3 1,8 0,5 0 CV death Non-fatal MI Non-fatal stroke CV death / MI / stroke All p values <0.001 *Pts with 3 risk factors but no symptoms are counted as 0, even in the presence of asymptomatic carotid plaque or reduced ABI **TIA, unstable angina, other ischemic arterial event including worsening of peripheral arterial disease Steg PG et al. JAMA. 2007

Identification of Presymtomatic CAD Individuals Among Stroke Patients Acute Coronary Syndrome Following Stroke: Data from RCTs Acute phase of Stroke/TIA (IST, ECASS-I, TOAST) : Risk of Fatal ACS : 2 to 5% at 90 days Among 846 ischemic stroke patients in the Virtual International Stroke Trials Archive, 35 (4.1%) died from cardiac causes at 12 weeks (Prosser J et al. Stroke 2007;38:2295-302) Long-term prevention trials: Risk of Fatal ACS : 2 to 2.5% between day-30 and month-24 post stroke (ESPS-2) 5% at 3 years in TASS

Vascular Prognosis in Stroke Patients CHD and Vascular Death Risk After a Stroke Meta-Analysis of RCTs and Epidemiological Studies 25 Vascular Death 25 Total MI 20 20 15 % 15 % 10 10 5 5 0 0 2 4 6 8 10 Follow-up (years) 0 0 2 4 6 8 10 Follow-up (years) Non-fatal MI Fatal MI 10 20 7.5 15 % % 5 10 2.5 5 0 0 2 4 6 8 10 Follow-up (years) Touzé E, et al. Stroke. 2005;36:2748-2755. 0 0 2 4 6 8 10 Follow-up (years)

Estimated Hazard Rate Relationship Between Stroke and Major Coronary Event Risk 1.2x10-4 1x10-4 Placebo: Stroke Placebo: Major Coronary Event 8x10-5 6x10-5 4x10-5 2x10-5 0 0 1 2 3 4 5 6 Years Since Randomization Amarenco P et al. Stroke. 2010

Stroke Subtypes and Any CHD Event Risk Atorvastatin Estimated Risk per Person-Year N=2365 (%) All Subjects 1.1 Entry Event TIA 1.0 Stroke 1.2 Ischemic 1.2 Cardioembolic or Large Vessel 1.4 Small Vessel 1.3 Other Ischemic 1.0 Hemorrhagic 1.0 Placebo N=2366 1.9 1.8 2.0 2.0 1.9 2.1 1.7 2.3 Amarenco P et al. Stroke. 2010

Identification of Presymtomatic CAD Individuals Among Stroke Patients Exercise T1-201 Myocardial Scintigraphy Rokey: positive in 41% of 34 stroke patients without cardiac symptoms Di Pasquale: positive in 26% of 190 stroke/tia patients without cardiac symptoms

Total Heart 2005 Identification of Presymtomatic CAD Individuals Among Stroke Patients Coronary Angiography in 420 Carotid Stenting Past CAD n=166 ; No past CAD n=254 One-vessel disease 70 17% Two-vessel disease 64 15% Three-vessel disease 93 22% Left main stenosis 31 07%

Identification of Presymtomatic CAD Individuals Among Stroke Patients Multiple Atherosclerotic Sites in Stroke (MASS) Autopsy study Coronary artery plaque : 72.2% (254/352) Coronary artery stenosis : 38.1% (131/344) Plaque: OR Stroke= 3.62 (95% CI, 2.54-5.16, p<0.0001) Stenosis: OR Stroke= 2.59 (95% CI, 1.72-3.89, p<0.0001) Gongora, Labreuche, Jaramillo, Steg, Hauw, Amarenco. Stroke. 2007.

MASS Autopsy Study: Prevalence of CAD in 808 Patients with Fatal Stroke 808 Autopsies 100 Coronary Plaque Coronary Stenosis>50% MI (silent or not) 80 74% 60 68% 40 44% 20 0 39% 33% 32% * 27% * * 13% 10% BI ATH CE Lacunar UNK BH OND N = 251 60 90 24 32 90 462 * P<.001 for the comparison with patients with cerebrovascular disease Gongora F, Labreuche J, Jaramillo A, Steg PG, Hauw J-J, Amarenco P. Stroke. 2007

MASS Autopsy Study: 381 Patients With Stroke Autopsy Prevalence of Coronary Plaque, Stenosis, or Myocardial Infarction in Case of Brain Artery Stenosis 100 Coronary Plaques 100 Coronary Plaques 80 Coronary Stenosis Myocardial Infarction 80 Coronary Stenosis Myocardial Infarction 60 60 % 40 % 40 20 20 0 No Plaque Plaque Stenosis 30% or Occlusion 0 No Plaque Plaque Stenosis 30% or Occlusion on Cerebral Arteries on Cerebral Arteries Any Segment of the Cerebral Arteries Internal Carotid Artery Origin Gongora F, Labreuche J, Jaramillo A, Steg PG, Hauw J-J, Amarenco P. Stroke. 2007

Prevalence of Coronary Atherosclerosis in Stroke Patients Prevalence of Asymptomatic Coronary Artery Disease Among 315 Patients with no History of Coronary Heart Disease Coronary Plaque Coronary Stenosis 50 % Number of vessel disease Amarenco P et al. Stroke. 2011;42:22-29

PRECORIS study Using 64-section Coronary CT angiography 20% of 274 patients with noncardioembolic stroke or TIA have coronary artery stenosis 50% Calvet et al. Circulation. 2010

In summary : - Asymptomatic coronary atherosclerosis is highly prevalent in stroke patients However, in stroke patients : Do we have to actively search for asymptomatic CAD? Does asymptomatic coronary atherosclerosis predict a higher risk of major vascular event? Can we further interfere with this risk?

AMISTAD STUDY DESIGN Consecutive inclusion All ischemic stroke over 3.5 years (between June 2005 and December 2008) 405 patients (regardless of ischemic stroke subtype) 63 with known CHD (15.6%) 342 with no known CHD 315 (92.1%) had coronary angiography within a median 8 (interquartile range, 6 to 11) days after stroke onset 27 either refused CA after inclusion or had a contra-indication Informed consent signed by all patients IRB approval

AMISTAD STUDY DESIGN Risk Factor Evaluation Standardized Etiological Investigations Evaluation of Extra Coronary Atherosclerosis Disease Burden US examination of both extracranial carotid arteries US examination of both femoral arteries

AMISTAD STUDY DESIGN Follow-up : 3 months, 6 months, 1 and 2 years Face to face interview by stroke neurologist or structured telephone interview (patient, close relative or family doctor) Blood pressure, Lipid profile, Treatment and Outcome Event Outcome Event : TIME TO FIRST MAJOR VASCULAR EVENT Vascular Death (Fatal stroke, Fatal MI, Other Cardiovascular death) Non Fatal Sroke Non Fatal Cardiac Event (MI, resuscitation after cardiac arrest, hospitalization for unstable angina or cardiac insufficiency) Major Peripheral Event (non cervicocephalic or cardiac disease leading to hospitalization or revascularization)

AMISTAD STUDY RESULTS : Baseline characteristics 378 Patients included in the FU analysis, 6 had no information

AMISTAD STUDY RESULTS : Mean Baseline and Follow-up SBP and LDL-C Levels by Baseline Coronary Artery Disease Subgroups. 95% Confidence Intervals are plotted. Average decrease of 9 mm Hg Average decrease of 40 mg/dl (1 mmol/l)

AMISTAD STUDY RESULTS : Cumulative Incidence Curves of Composite End Point of Major Vascular events in the Baseline Coronary Artery Disease Subgroups

AMISTAD STUDY RESULTS : Association of Two-Year Vascular Risk with Presence and Severity of Asymptomatic Coronary Artery Disease Diagnosed at Baseline.

AMISTAD STUDY RESULTS : Impact of arterial atherosclerotic burden of coronary, extracranial carotid and femoral arteries on Vascular Risk Recurrence 20 Age-sex-adjusted p for trend=0.041 Two-year vascular risk, % 15 10 5 2.6 4.3 12.5 15.3 0 0 (n=40) 1 (n=71) 2 (n=91) 3 (n=170) Number of arterial disease locations * * coronary, extracranial carotid and femoral arteries

CONCLUSIONS : In patients with recent non fatal cerebral infarction: Asymptomatic CAD is highly predictive of any future major vascular event within 2 years after stroke The risk of major vascular events increased with the extent of atherosclerotic disease:. Number of coronary arteries involved. Number of vascular beds involved Long-term follow-up is in progress to confirm these results Further studies are required to test more aggressive preventive strategies in stroke/tia patients